Publication details

Agonist of the adenosine A(3) receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of gamma-irradiated mice

Investor logo
Authors

HOFER Michal POSPÍŠIL Milan DUŠEK Ladislav HOFEROVÁ Zuzana KOMURKOVA Denisa

Year of publication 2014
Type Article in Periodical
Magazine / Source Radiation and Environmental Biophysics
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1007/s00411-013-0500-y
Field Biophysics
Keywords Ionizing radiation; Acute radiation disease; Survival; Adenosine A(3) receptor agonist; Cyclooxygenase-2 inhibitor
Description There exists a requirement for drugs which would be useful in therapy of an acute radiation damage of a mammalian organism. The aim of the study was to evaluate survival parameters in mice exposed to a lethal gamma-ray dose of 8.5 Gy and treated with single doses of an adenosine A(3) receptor agonist, IB-MECA, or a cyclooxygenase-2 (COX-2) inhibitor, meloxicam, administered alone or in a combination early after irradiation, i.e., 0.5 and 1 h post-irradiation, respectively. The assessed parameters were the mean survival time (MST) and the cumulative percentage 30-day survival (CPS). Administrations of single intraperitoneal doses of either IB-MECA 0.5 h post-irradiation or meloxicam 1 h post-irradiation resulted in statistically significant increases of MST in comparison with the control irradiated mice. Combined administration of IB-MECA and meloxicam was found to be the only treatment statistically enhancing the parameter of CPS and to lead to the most expressive increase in MST of the experimental mice. The findings add new knowledge on the action of an adenosine A(3) receptor agonist and a COX-2 inhibitor in an irradiated mammalian organism and suggest the potential of both the investigated drugs in the treatment of the acute radiation damage.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info